Allergic bronchopulmonary aspergillosis in cystic fibrosis: Case-control study from the French registry.

IF 2.7 3区 医学 Q3 INFECTIOUS DISEASES
Marine Tarizzo, Lydie Lemonnier, Soline Leblanc, Jeanne Bigot, Guillaume Thouvenin, Loïc Guillot, Harriet Corvol
{"title":"Allergic bronchopulmonary aspergillosis in cystic fibrosis: Case-control study from the French registry.","authors":"Marine Tarizzo, Lydie Lemonnier, Soline Leblanc, Jeanne Bigot, Guillaume Thouvenin, Loïc Guillot, Harriet Corvol","doi":"10.1093/mmy/myaf030","DOIUrl":null,"url":null,"abstract":"<p><p>Allergic bronchopulmonary aspergillosis (ABPA) is a significant complication in people with cystic fibrosis (pwCF), driven by hypersensitivity to Aspergillus fumigatus. This study aimed to identify factors associated with the development of ABPA in pwCF, using data from the French CF Registry (FCFR). We conducted a multicenter case-control study utilizing anonymized data from the FCFR, spanning the period from 2016 to 2021. A total of 312 ABPA cases were matched to 936 controls. Various clinical factors, including CFTR variants, nutritional status, glucose disorders, respiratory function, chronic bacterial colonization, and treatments such as antibiotics, corticosteroids, and antifungals, were analyzed. Multivariate analyses and logistic regression models were used to identify associations with ABPA. PwCF who received more frequent intravenous antibiotics (OR = 2.47, P = .013), long-term inhaled corticosteroids (OR = 1.82, P < .001), or antifungals (OR = 5.83, P < .0001) exhibited a higher likelihood of developing ABPA. Additionally, glucose disorders were significantly associated with ABPA (OR = 1.41, P = .03). In contrast, a higher body mass index (BMI >25 kg/m²) appeared to be a protective factor (OR = 0.47, P = .03). No significant associations were observed with lung function, CFTR variants, or chronic Pseudomonas aeruginosa colonization. These findings suggest that certain clinical factors and treatments, particularly glucose disorders, frequent antibiotic use, and corticosteroid therapy, are associated with the development of ABPA in pwCF. Notably, a higher BMI may have a protective effect. Further research is needed to explore the underlying mechanisms of these associations and optimize treatment strategies for ABPA in CF, especially as CF therapies continue to evolve.</p>","PeriodicalId":18586,"journal":{"name":"Medical mycology","volume":"63 4","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11992956/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical mycology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/mmy/myaf030","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Allergic bronchopulmonary aspergillosis (ABPA) is a significant complication in people with cystic fibrosis (pwCF), driven by hypersensitivity to Aspergillus fumigatus. This study aimed to identify factors associated with the development of ABPA in pwCF, using data from the French CF Registry (FCFR). We conducted a multicenter case-control study utilizing anonymized data from the FCFR, spanning the period from 2016 to 2021. A total of 312 ABPA cases were matched to 936 controls. Various clinical factors, including CFTR variants, nutritional status, glucose disorders, respiratory function, chronic bacterial colonization, and treatments such as antibiotics, corticosteroids, and antifungals, were analyzed. Multivariate analyses and logistic regression models were used to identify associations with ABPA. PwCF who received more frequent intravenous antibiotics (OR = 2.47, P = .013), long-term inhaled corticosteroids (OR = 1.82, P < .001), or antifungals (OR = 5.83, P < .0001) exhibited a higher likelihood of developing ABPA. Additionally, glucose disorders were significantly associated with ABPA (OR = 1.41, P = .03). In contrast, a higher body mass index (BMI >25 kg/m²) appeared to be a protective factor (OR = 0.47, P = .03). No significant associations were observed with lung function, CFTR variants, or chronic Pseudomonas aeruginosa colonization. These findings suggest that certain clinical factors and treatments, particularly glucose disorders, frequent antibiotic use, and corticosteroid therapy, are associated with the development of ABPA in pwCF. Notably, a higher BMI may have a protective effect. Further research is needed to explore the underlying mechanisms of these associations and optimize treatment strategies for ABPA in CF, especially as CF therapies continue to evolve.

囊性纤维化患者的过敏性支气管肺曲霉病:来自法国注册中心的病例对照研究。
过敏性支气管肺曲霉病(ABPA)是囊性纤维化(pwCF)患者的重要并发症,由对烟曲霉过敏引起。本研究旨在利用法国CF登记处(FCFR)的数据,确定与pwCF中ABPA发展相关的因素。我们利用FCFR的匿名数据进行了一项多中心病例对照研究,时间跨度为2016年至2021年。共有312例ABPA病例与936例对照。分析了各种临床因素,包括CFTR变异、营养状况、血糖紊乱、呼吸功能、慢性细菌定植以及抗生素、皮质类固醇和抗真菌药物等治疗方法。使用多变量分析和逻辑回归模型来确定与ABPA的关联。频繁静脉注射抗生素(OR = 2.47, P = 0.013)和长期吸入皮质类固醇(OR = 1.82, P 25 kg/m²)似乎是PwCF的保护因素(OR = 0.47, P = 0.03)。未观察到与肺功能、CFTR变异或慢性铜绿假单胞菌定植有显著关联。这些发现表明,某些临床因素和治疗,特别是血糖紊乱、频繁使用抗生素和皮质类固醇治疗,与pwCF中ABPA的发生有关。值得注意的是,较高的身体质量指数可能具有保护作用。需要进一步的研究来探索这些关联的潜在机制,并优化CF中ABPA的治疗策略,特别是随着CF治疗方法的不断发展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Medical mycology
Medical mycology 医学-兽医学
CiteScore
5.70
自引率
3.40%
发文量
632
审稿时长
12 months
期刊介绍: Medical Mycology is a peer-reviewed international journal that focuses on original and innovative basic and applied studies, as well as learned reviews on all aspects of medical, veterinary and environmental mycology as related to disease. The objective is to present the highest quality scientific reports from throughout the world on divergent topics. These topics include the phylogeny of fungal pathogens, epidemiology and public health mycology themes, new approaches in the diagnosis and treatment of mycoses including clinical trials and guidelines, pharmacology and antifungal susceptibilities, changes in taxonomy, description of new or unusual fungi associated with human or animal disease, immunology of fungal infections, vaccinology for prevention of fungal infections, pathogenesis and virulence, and the molecular biology of pathogenic fungi in vitro and in vivo, including genomics, transcriptomics, metabolomics, and proteomics. Case reports are no longer accepted. In addition, studies of natural products showing inhibitory activity against pathogenic fungi are not accepted without chemical characterization and identification of the compounds responsible for the inhibitory activity.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信